Zura Bio Limited (NASDAQ:ZURA) Given Consensus Rating of "Moderate Buy" by Brokerages

Key Points

• Zura Bio has a “Moderate Buy” consensus rating from eight analysts, with five buys, one strong buy, one hold and one sell. The average 12-month price target is $14.00, while Wedbush and Guggenheim recently raised their targets to $22 and $20, respectively.
• Institutional investors and hedge funds own 61.14% of Zura Bio’s shares, with several firms recently initiating or increasing positions.
• ZURA opened at $5.57, within a 12-month range of $1.64 to $7.44, and reported a quarterly loss of $0.21 per share. Analysts expect a full-year loss of approximately $0.81 per share.

Shares of Zura Bio Limited (NASDAQ:ZURA - Get Free Report) have received an average rating of "Moderate Buy" from the eight ratings firms that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, five have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $14.00.

Several research analysts have issued reports on the company. Wedbush upped their price target on Zura Bio from $15.00 to $22.00 and gave the company an "outperform" rating in a report on Wednesday. William Blair began coverage on Zura Bio in a research note on Wednesday, July 8th. They set an "outperform" rating for the company. Weiss Ratings reissued a "sell (d-)" rating on shares of Zura Bio in a research note on Monday, July 6th. Guggenheim lifted their target price on Zura Bio from $15.00 to $20.00 and gave the stock a "buy" rating in a report on Wednesday. Finally, Wall Street Zen raised Zura Bio from a "strong sell" rating to a "sell" rating in a research report on Saturday, August 1st.

Institutional Trading of Zura Bio

Several institutional investors and hedge funds have recently bought and sold shares of ZURA. Allworth Financial LP purchased a new position in Zura Bio during the 4th quarter worth approximately $30,000. Squarepoint Ops LLC lifted its holdings in shares of Zura Bio by 34.6% in the fourth quarter. Squarepoint Ops LLC now owns 33,801 shares of the company's stock valued at $177,000 after purchasing an additional 8,680 shares in the last quarter. Bank of America Corp DE lifted its holdings in shares of Zura Bio by 31.9% in the fourth quarter. Bank of America Corp DE now owns 41,222 shares of the company's stock valued at $103,000 after purchasing an additional 9,966 shares in the last quarter. Renaissance Technologies LLC boosted its position in shares of Zura Bio by 3.4% in the first quarter. Renaissance Technologies LLC now owns 313,300 shares of the company's stock worth $1,864,000 after buying an additional 10,200 shares during the period. Finally, Scientech Research LLC acquired a new stake in shares of Zura Bio in the third quarter worth $45,000. Institutional investors and hedge funds own 61.14% of the company's stock.

Zura Bio Price Performance

Shares of ZURA opened at $5.57 on Monday. The firm's 50 day moving average is $4.99 and its 200-day moving average is $5.39. Zura Bio has a 12-month low of $1.64 and a 12-month high of $7.44. The stock has a market capitalization of $528.48 million, a P/E ratio of -4.93 and a beta of -0.02.

Zura Bio (NASDAQ:ZURA - Get Free Report) last released its earnings results on Tuesday, June 30th. The company reported ($0.21) EPS for the quarter. As a group, equities research analysts forecast that Zura Bio will post -0.81 EPS for the current fiscal year.

Zura Bio Company Profile

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source